Phylo, Inc.

Phylo, Inc. , located in South San Francisco, US, specializes in AI-driven bioinformatics solutions focused on enhancing biological research efficiency and accuracy for academic and biotechnology sectors. Founded in 2025, Phylo, Inc. offers a collaborative bioinformatics platform aimed at improving scientific data workflows.

The company was established by Kexin Huang and Yuanhao Qu and has not undergone any notable pivots or changes since its inception. Its headquarters is situated in South San Francisco, US. Recently, Phylo, Inc. completed its Seed funding round on February 3, 2026, raising USD 13.

5 mn from key investors including Andreessen Horowitz and Menlo Ventures, bringing the total amount raised to USD 13. 5 mn and the current company valuation to USD 53. 21 mn. Phylo's primary offering, Biomni Lab, serves as a collaborative bioinformatics platform designed to enhance the efficiency and accuracy of biological research.

This advanced tool integrates seamlessly within the biomedical research ecosystem, allowing biologists to engage with AI-driven agents for diverse tasks such as protein design, multi-omics data analysis, and the synthesis of literature insights. By automating complex processes that traditionally consume weeks of labor, Biomni Lab accelerates discovery and fosters innovative hypotheses through its critical analysis capabilities. The product is targeted at academic institutions, biotechnology firms, and research organizations across North America and Europe, catering to professionals such as biologists, data scientists, and neuroscientists who require rigorous and expedited research tools. Phylo generates revenue primarily through subscription-based access to its Biomni Lab services, catering to both individual researchers and institutional clients.

Clients typically engage with the service on a recurring basis, utilizing tiered subscription plans that provide varying levels of access and features according to their specific research needs. For instance, institutions may opt for an enterprise-level subscription that encompasses multiple user licenses and enhanced computational resources, while individual researchers might select a personal plan for streamlined access. This transaction structure emphasizes long-term partnerships with academic and biotech organizations, enabling Phylo to establish a stable revenue stream through consistent patronage and usage of its technology. In February 2026, Phylo, Inc.

raised USD 13. 5 mn in Seed funding co-led by Andreessen Horowitz and Menlo Ventures, with additional participation from Zetta Venture Partners, Conviction, and SV Angel. The company plans to utilize this funding to continue developing its AI-powered biology platform to further streamline scientific data workflows. Future product developments are expected to enhance the features of Biomni Lab, although specific release dates have not been disclosed.

Additionally, Phylo aims to expand its services into new markets, particularly targeting increased engagement in Europe and North America by 2027.